{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:53:07Z","timestamp":1769082787035,"version":"3.49.0"},"reference-count":164,"publisher":"Bentham Science Publishers Ltd.","issue":"9","funder":[{"DOI":"10.13039\/501100006409","name":"Ministry of Education of Greece","doi-asserted-by":"publisher","award":["THALIS MIS 377286"],"award-info":[{"award-number":["THALIS MIS 377286"]}],"id":[{"id":"10.13039\/501100006409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003448","name":"General Secretariat of Research and Technology of Greece","doi-asserted-by":"publisher","award":["SYNERGASIA 09SYN-12-897"],"award-info":[{"award-number":["SYNERGASIA 09SYN-12-897"]}],"id":[{"id":"10.13039\/501100003448","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,5,21]]},"abstract":"<jats:sec><jats:title\/><jats:p>The \u201cHDL hypothesis\u201d which suggested that an elevation in HDL cholesterol (HDL-C) levels by drugs or by life style changes should be paralleled by a decrease in the risk for Cardiovascular Disease (CVD) has been challenged by recent epidemiological and clinical studies using HDL-raising drugs. HDL components such as proteins, lipids or small RNA molecules, but not cholesterol itself, possess various atheroprotective functions in different cell types and accumulating evidence supports the new hypothesis that HDL functionality is more important than HDL-C levels for CVD risk prediction. Thus, the detailed characterization of changes in HDL composition and functions in various pathogenic conditions is critically important in order to identify new biomarkers for diagnosis, prognosis and therapy monitoring of CVD. Here we provide an overview of how HDL composition, size and functionality are affected in patients with monogenic disorders of HDL metabolism due to mutations in genes that participate in the biogenesis and the remodeling of HDL. We also review the findings from various mouse models with genetic disturbances in the HDL biogenesis pathway that have been generated for the validation of the data obtained in human patients and how these models could be utilized for the evaluation of novel therapeutic strategies such as the use of adenovirus-mediated gene transfer technology that aim to correct HDL abnormalities.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867325666180313114950","type":"journal-article","created":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T11:59:39Z","timestamp":1520942379000},"page":"1544-1575","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling"],"prefix":"10.2174","volume":"26","author":[{"given":"Angeliki","family":"Chroni","sequence":"first","affiliation":[{"name":"Institute of Biosciences and Applications, National Center for Scientific Research , Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitris","family":"Kardassis","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, University of Crete Medical School and Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology of Hellas, Heraklion 71003, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","volume":"79","author":"Gordon D.J.","year":"1989","unstructured":"Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.","journal-title":"Circulation"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"Di Angelantonio E.","year":"2009","unstructured":"Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease.","journal-title":"JAMA"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00392-017-1106-1","volume":"106","author":"Marz W.","year":"2017","unstructured":"Marz W, Kleber ME, Scharnagl H, Speer T, Zewinger S, Ritsch A, Parhofer KG. von, Eckardstein A.; Landmesser, U.; Laufs, U. HDL cholesterol: reappraisal of its clinical relevance.","journal-title":"Clin Res Cardiol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"Voight B.F.","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A. de, F.U.; Gigante, B.; Ingelsson, E.; Zeller, T.; Wild, P.; de Bakker, P.I.; Klungel, O.H.; Maitland-van der Zee AH; Peters, B.J.; de, B.A.; Grobbee, D.E.; Kamphuisen, P.W.; Deneer, V.H.; Elbers, C.C.; Onland-Moret, N.C.; Hofker, M.H.; Wijmenga, C.; Verschuren, W.M.; Boer, J.M.; van der Schouw, Y.T.; Rasheed, A.; Frossard, P.; Demissie, S.; Willer, C.; Do, R.; Ordovas, J.M.; Abecasis, G.R.; Boehnke, M.; Mohlke, K.L.; Daly, M.J.; Guiducci, C.; Burtt, N.P.; Surti, A.; Gonzalez, E.; Purcell, S.; Gabriel, S.; Marrugat, J.; Peden, J.; Erdmann, J.; Diemert, P.; Willenborg, C.; Konig, I.R.; Fischer, M.; Hengstenberg, C.; Ziegler, A.; Buysschaert, I.; Lambrechts, D.; Van de Werf, F.; Fox, K.A.; El Mokhtari, N.E.; Rubin, D.; Schrezenmeir, J.; Schreiber, S.; Schafer, A.; Danesh, J.; Blankenberg, S.; Roberts, R.; McPherson, R.; Watkins, H.; Hall, A.S.; Overvad, K.; Rimm, E.; Boerwinkle, E.; Tybjaerg-Hansen, A.; Cupples, L.A.; Reilly, M.P.; Melander, O.; Mannucci, P.M.; Ardissino, D.; Siscovick, D.; Elosua, R.; Stefansson, K.; O&#x2019;Donnell, C.J.; Salomaa, V.; Rader, D.J.; Peltonen, L.; Schwartz, S.M.; Altshuler, D.; Kathiresan, S. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study.","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-09665-0_1","volume":"224","author":"Kontush A.","year":"2015","unstructured":"Kontush A, Lindahl M, Lhomme M, Calabresi L, Chapman MJ, Davidson WS. Structure of HDL: Particle subclasses and molecular components.","journal-title":"Handb Exp Pharmacol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbalip.2017.05.010","volume":"1862","author":"Cukier A.M.O.","year":"2017","unstructured":"Cukier AMO, Therond P, Didichenko SA, Guillas I, Chapman MJ, Wright SD, Kontush A. Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.","journal-title":"Biochim Biophys Acta"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0009-8981(99)00096-0","volume":"286","author":"Duriez P.","year":"1999","unstructured":"Duriez P, Fruchart JC. High-density lipoprotein subclasses and apolipoprotein A-I.","journal-title":"Clin Chim Acta"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1194\/jlr.M700362-JLR200","volume":"49","author":"Santos R.D.","year":"2008","unstructured":"Santos RD, Schaefer EJ, Asztalos BF, Polisecki E, Wang J, Hegele RA, Martinez LR, Miname MH, Rochitte CE, Da Luz PL, Maranhao RC. Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency.","journal-title":"J Lipid Res"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-2275(20)39898-9","volume":"36","author":"Fielding C.J.","year":"1995","unstructured":"Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport.","journal-title":"J Lipid Res"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/01.ATV.0000183727.90611.4f","volume":"25","author":"Asztalos B.F.","year":"2005","unstructured":"Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1194\/jlr.M300198-JLR200","volume":"45","author":"Asztalos B.F.","year":"2004","unstructured":"Asztalos BF, Horvath KV, Kajinami K, Nartsupha C, Cox CE, Batista M, Schaefer EJ, Inazu A, Mabuchi H. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency.","journal-title":"J Lipid Res"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1194\/jlr.R035964","volume":"55","author":"Vickers K.C.","year":"2014","unstructured":"Vickers KC, Remaley AT. HDL and cholesterol: life after the divorce?","journal-title":"J Lipid Res"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1172\/JCI26206","volume":"117","author":"Vaisar T.","year":"2007","unstructured":"Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.","journal-title":"J Clin Invest"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1194\/jlr.R035725","volume":"54","author":"Shah A.S.","year":"2013","unstructured":"Shah AS, Tan L, Lu LJ, Davidson WS. The proteomic diversity of high density lipoproteins: Our emerging understanding of its importance in lipid transport and beyond.","journal-title":"J Lipid Res"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1194\/jlr.D800028-JLR200","volume":"50","author":"Wiesner P.","year":"2009","unstructured":"Wiesner P, Leidl K, Boettcher A, Schmitz G, Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry.","journal-title":"J Lipid Res"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1161\/ATVBAHA.113.301468","volume":"33","author":"Camont L.","year":"2013","unstructured":"Camont L, Lhomme M, Rached F, Le GW, Negre-Salvayre A, Salvayre R, Calzada C, Lagarde M, Chapman MJ, Kontush A. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1039\/c2mb25115a","volume":"8","author":"Hyotylainen T.","year":"2012","unstructured":"Hyotylainen T, Mattila I, Wiedmer SK, Koivuniemi A, Taskinen MR, Yki-Jarvinen H, Oresic M. Metabolomic analysis of polar metabolites in lipoprotein fractions identifies lipoprotein-specific metabolic profiles and their association with insulin resistance.","journal-title":"Mol Biosyst"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","volume":"13","author":"Vickers K.C.","year":"2011","unstructured":"Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.","journal-title":"Nat Cell Biol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbalip.2011.07.013","volume":"1821","author":"Alwaili K.","year":"2012","unstructured":"Alwaili K, Bailey D, Awan Z, Bailey SD, Ruel I, Hafiane A, Krimbou L, Laboissiere S, Genest J. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile.","journal-title":"Biochim Biophys Acta"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1253\/circj.CJ-13-1025","volume":"77","author":"Annema W.","year":"2013","unstructured":"Annema W, von Eckardstein A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis.","journal-title":"Circ J"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-319-09665-0_2","volume":"224","author":"Zannis V.I.","year":"2015","unstructured":"Zannis VI, Fotakis P, Koukos G, Kardassis D, Ehnholm C, Jauhiainen M, Chroni A. HDL biogenesis, remodeling, and catabolism.","journal-title":"Handb Exp Pharmacol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/bi00337a028","volume":"24","author":"Zannis V.I.","year":"1985","unstructured":"Zannis VI, Cole FS, Jackson CL, Kurnit DM, Karathanasis SK. Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages.","journal-title":"Biochemistry"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1050-1738(01)00163-3","volume":"12","author":"Sorci-Thomas M.G.","year":"2002","unstructured":"Sorci-Thomas MG, Thomas MJ. The effects of altered apolipoprotein A-I structure on plasma HDL concentration.","journal-title":"Trends Cardiovasc Med"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.atherosclerosis.2005.10.033","volume":"186","author":"von Eckardstein A.","year":"2006","unstructured":"von Eckardstein A. Differential diagnosis of familial high density lipoprotein deficiency syndromes.","journal-title":"Atherosclerosis"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"22E","DOI":"10.1016\/j.amjcard.2009.09.016","volume":"104","author":"Strang A.C.","year":"2009","unstructured":"Strang AC, Hovingh GK, Stroes ES, Kastelein JJ. The genetics of high-density lipoprotein metabolism: Clinical relevance for therapeutic approaches.","journal-title":"Am J Cardiol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.arcmed.2015.05.012","volume":"46","author":"Mei X.","year":"2015","unstructured":"Mei X, Atkinson D. Lipid-free apolipoprotein A-I structure: Insights into HDL formation and atherosclerosis development.","journal-title":"Arch Med Res"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0022-2275(20)37433-2","volume":"38","author":"Kuivenhoven J.A.","year":"1997","unstructured":"Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:Cholesterol acyltransferase (LCAT) deficiency syndromes.","journal-title":"J Lipid Res"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00109-005-0030-4","volume":"84","author":"Zannis V.I.","year":"2006","unstructured":"Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL.","journal-title":"J Mol Med"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.atherosclerosis.2017.01.034","volume":"258","author":"Hoekstra M.","year":"2017","unstructured":"Hoekstra M. SR-BI as target in atherosclerosis and cardiovascular disease - A comprehensive appraisal of the cellular functions of SR-BI in physiology and disease.","journal-title":"Atherosclerosis"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"45980","DOI":"10.1074\/jbc.M408652200","volume":"279","author":"Nakamura K.","year":"2004","unstructured":"Nakamura K, Kennedy MA, Baldan A, Bojanic DD, Lyons K, Edwards PA. Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs\/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein.","journal-title":"J Biol Chem"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"30150","DOI":"10.1074\/jbc.M505368200","volume":"280","author":"Vaughan A.M.","year":"2005","unstructured":"Vaughan AM, Oram JF. ABCG1 redistributes cell cholesterol to domains removable by HDL but not by lipid-depleted apolipoproteins.","journal-title":"J Biol Chem"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1161\/01.CIR.0000092889.24713.DC","volume":"108","author":"Maugeais C.","year":"2003","unstructured":"Maugeais C, Tietge UJ, Broedl UC, Marchadier D, Cain W, McCoy MG, Lund-Katz S, Glick JM, Rader DJ. Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase.","journal-title":"Circulation"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/01.ATV.0000140818.00570.2d","volume":"24","author":"Santamarina-Fojo S.","year":"2004","unstructured":"Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","volume":"23","author":"Barter P.J.","year":"2003","unstructured":"Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00041433-200406000-00004","volume":"15","author":"Albers J.J.","year":"2004","unstructured":"Albers JJ, Cheung MC. Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism.","journal-title":"Curr Opin Lipidol"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Siggins, S.; Rye, K.A.; Olkkonen, V.M.; Jauhiainen, M.; Ehnholm, C. Human plasma phospholipid transfer protein (PLTP) - structural and functional features. In. High- Density lipoproteins.From Basic Biology to Clinical Aspects, Fielding, C.J., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2007; pp. 183-205","DOI":"10.1002\/9783527625178.ch8"},{"key":"ref=37","unstructured":"Brunzell, J.D. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome.In The Metabolic and Molecular Basis of Inherited Disease; Scriver, C.R.; Beaudet, A.L.; Sly, W.S.; Valle, D., Eds.; McGraw-Hill: New York, 1995, pp. 1913-1932."},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/01.ATV.0000203512.01007.3d","volume":"26","author":"Zheng C.","year":"2006","unstructured":"Zheng C, Murdoch SJ, Brunzell JD, Sacks FM. Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1194\/jlr.R004739","volume":"51","author":"Weissglas-Volkov D.","year":"2010","unstructured":"Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol.","journal-title":"J Lipid Res"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCGENETICS.111.962613","volume":"6","author":"Singaraja R.R.","year":"2013","unstructured":"Singaraja RR, Sivapalaratnam S, Hovingh K, Dube MP, Castro-Perez J, Collins HL, Adelman SJ, Riwanto M, Manz J, Hubbard B, Tietjen I, Wong K, Mitnaul LJ, van Heek M, Lin L, Roddy TA, McEwen J, Dallinge-Thie G. van Vark-van der Zee; Verwoert, G.; Winther, M.; van Duijn, C.; Hofman, A.; Trip, M.D.; Marais, A.D.; Asztalos, B.; Landmesser, U.; Sijbrands, E.; Kastelein, J.J.; Hayden, M.R. The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans.","journal-title":"Circ Cardiovasc Genet"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/MOL.0000000000000396","volume":"28","author":"Trigatti B.L.","year":"2017","unstructured":"Trigatti BL. -B1 and PDZK1: partners in HDL regulation.","journal-title":"Curr Opin Lipidol"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa0907687","volume":"364","author":"Vergeer M.","year":"2011","unstructured":"Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, Hovingh GK, Hoekstra M, Sierts JA, Dallinga-Thie GM, Motazacker MM, Holleboom AG, van Berkel TJ, Kastelein JJ, Van Eck M, Kuivenhoven JA. Genetic variant of the scavenger receptor BI in humans.","journal-title":"N Engl J Med"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.aad3517","volume":"351","author":"Zanoni P.","year":"2016","unstructured":"Zanoni P, Khetarpal SA, Larach DB, Hancock-Cerutti WF, Millar JS, Cuchel M, Derohannessian S, Kontush A, Surendran P, Saleheen D, Trompet S, Jukema JW, De CA, Deloukas P, Sattar N, Ford I, Packard C, Majumder A, Alam DS, Di AE, Abecasis G, Chowdhury R, Erdmann J, Nordestgaard BG, Nielsen SF, Tybjaerg-Hansen A, Schmidt RF, Kuulasmaa K, Liu DJ, Perola M, Blankenberg S, Salomaa V, Mannisto S, Amouyel P, Arveiler D, Ferrieres J, Muller-Nurasyid M, Ferrario M, Kee F, Willer CJ, Samani N, Schunkert H, Butterworth AS, Howson JM, Peloso GM, Stitziel NO, Danesh J, Kathiresan S, Rader DJ. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease.","journal-title":"Science"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","volume":"277","author":"Shimizugawa T.","year":"2002","unstructured":"Shimizugawa T, Ono M, Shimamura M, Yoshida K, Ando Y, Koishi R, Ueda K, Inaba T, Minekura H, Kohama T, Furukawa H. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase.","journal-title":"J Biol Chem"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","volume":"27","author":"Shimamura M.","year":"2007","unstructured":"Shimamura M, Matsuda M, Yasumo H, Okazaki M, Fujimoto K, Kono K, Shimizugawa T, Ando Y, Koishi R, Kohama T, Sakai N, Kotani K, Komuro R, Ishida T, Hirata K, Yamashita S, Furukawa H, Shimomura I. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","volume":"363","author":"Musunuru K.","year":"2010","unstructured":"Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, Garimella KV, Fisher S, Abreu J, Barry AJ, Fennell T, Banks E, Ambrogio L, Cibulskis K, Kernytsky A, Gonzalez E, Rudzicz N, Engert JC, DePristo MA, Daly MJ, Cohen JC, Hobbs HH, Altshuler D, Schonfeld G, Gabriel SB, Yue P, Kathiresan S. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia.","journal-title":"N Engl J Med"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCGENETICS.111.960674","volume":"5","author":"Pisciotta L.","year":"2012","unstructured":"Pisciotta L, Favari E, Magnolo L, Simonelli S, Adorni MP, Sallo R, Fancello T, Zavaroni I, Ardigo D, Bernini F, Calabresi L, Franceschini G, Tarugi P, Calandra S, Bertolini S. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3.","journal-title":"Circ Cardiovasc Genet"},{"key":"ref=48","unstructured":"Herbert, P.N.; Assmann, G.; Gotto, A.M., Jr; Fredrickson, D.S. Familial lipoprotein deficiency: Alpha beta lipoproteinemia, hypobetalipoproteinemia, and Tangier disease.In The Metabolic Basis of Inherited Disease; Stanbury, J.B.; Wyngaarden, J.B.; Fredrickson, D.S.; Goldstein, J.L.; Brown, M.S., Eds.; McGraw-Hill: New York, 1982, pp. 589-651."},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/01.RES.33.4.403","volume":"33","author":"Krauss R.M.","year":"1973","unstructured":"Krauss RM, Herbert PN, Levy RI, Fredrickson DS. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins.","journal-title":"Circ Res"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature09270","volume":"466","author":"Teslovich T.M.","year":"2010","unstructured":"Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin CY, Jin GM, Jin KY, Lee JY, Park T, Kim K, Sim X, Twee-Hee OR, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua ZJ, Yuan X, Luan J, Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Witteman JC, Wilson JF, Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruokonen A, Rudan I, Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BW, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O&#x2019;Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, Magnusson PK, Lucas G, Luben R, Loos RJ, Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, Konig IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR, Janssens AC, Ingelsson E, Igl W, Kees HG, Hottenga JJ, Hofman A, Hicks AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, Gyllensten U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Doring A, Dominiczak AF, Demissie S, Deloukas P, de Geus EJ. de, F.U.; Crawford, G.; Collins, F.S.; Chen, Y.D.; Caulfield, M.J.; Campbell, H.; Burtt, N.P.; Bonnycastle, L.L.; Boomsma, D.I.; Boekholdt, S.M.; Bergman, R.N.; Barroso, I.; Bandinelli, S.; Ballantyne, C.M.; Assimes, T.L.; Quertermous, T.; Altshuler, D.; Seielstad, M.; Wong, T.Y.; Tai, E.S.; Feranil, A.B.; Kuzawa, C.W.; Adair, L.S.; Taylor, H.A., Jr.; Borecki, I.B.; Gabriel, S.B.; Wilson, J.G.; Holm, H.; Thorsteinsdottir, U.; Gudnason, V.; Krauss, R.M.; Mohlke, K.L.; Ordovas, J.M.; Munroe, P.B.; Kooner, J.S.; Tall, A.R.; Hegele, R.A.; Kastelein, J.J.; Schadt, E.E.; Rotter, J.I.; Boerwinkle, E.; Strachan, D.P.; Mooser, V.; Stefansson, K.; Reilly, M.P.; Samani, N.J.; Schunkert, H.; Cupples, L.A.; Sandhu, M.S.; Ridker, P.M.; Rader, D.J.; van Duijn, C.M.; Peltonen, L.; Abecasis, G.R.; Boehnke, M.; Kathiresan, S. Biological, clinical and population relevance of 95 loci for blood lipids.","journal-title":"Nature"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature01250","volume":"421","author":"Martinez L.O.","year":"2003","unstructured":"Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X, Perret B, Barbaras R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis.","journal-title":"Nature"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.atherosclerosis.2014.11.017","volume":"238","author":"Martinez L.O.","year":"2015","unstructured":"Martinez LO, Najib S, Perret B, Cabou C, Lichtenstein L. Ecto-F1-ATPase\/P2Y pathways in metabolic and vascular functions of high density lipoproteins.","journal-title":"Atherosclerosis"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/9504","volume":"5","author":"Kozyraki R.","year":"1999","unstructured":"Kozyraki R, Fyfe J, Kristiansen M, Gerdes C, Jacobsen C, Cui S, Christensen EI, Aminoff M. de la, C.A.; Krahe, R.; Verroust, P.J.; Moestrup, S.K. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein.","journal-title":"Nat Med"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MOL.0000000000000294","volume":"27","author":"von Eckardstein A.","year":"2016","unstructured":"von Eckardstein A, Rohrer L. HDLs in crises.","journal-title":"Curr Opin Lipidol"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.113.000962","volume":"128","author":"Rosenson R.S.","year":"2013","unstructured":"Rosenson RS, Brewer HB, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Translation of high-density lipoprotein function into clinical practice: Current prospects and future challenges.","journal-title":"Circulation"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","volume":"13","author":"Rosenson R.S.","year":"2016","unstructured":"Rosenson RS, Brewer HB, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Dysfunctional HDL and atherosclerotic cardiovascular disease.","journal-title":"Nat Rev Cardiol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/MOL.0000000000000209","volume":"26","author":"Hutchins P.M.","year":"2015","unstructured":"Hutchins PM, Heinecke JW. Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL.","journal-title":"Curr Opin Lipidol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1172\/JCI200112810","volume":"108","author":"Haghpassand M.","year":"2001","unstructured":"Haghpassand M, Bourassa PA, Francone OL, Aiello RJ. Monocyte\/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels.","journal-title":"J Clin Invest"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/cvr\/cvu150","volume":"103","author":"Catapano A.L.","year":"2014","unstructured":"Catapano AL, Pirillo A, Bonacina F, Norata GD. HDL in innate and adaptive immunity.","journal-title":"Cardiovasc Res"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MOL.0000000000000260","volume":"27","author":"Chung S.","year":"2016","unstructured":"Chung S, Parks JS. Dietary cholesterol effects on adipose tissue inflammation.","journal-title":"Curr Opin Lipidol"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-3-319-09665-0_6","volume":"224","author":"Nofer J.R.","year":"2015","unstructured":"Nofer JR. Signal transduction by HDL: Agonists, receptors, and signaling cascades.","journal-title":"Handb Exp Pharmacol"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1194\/jlr.R039479","volume":"54","author":"Mineo C.","year":"2013","unstructured":"Mineo C, Shaul PW. Regulation of signal transduction by HDL.","journal-title":"J Lipid Res"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/978-3-319-09665-0_10","volume":"224","author":"Riwanto M.","year":"2015","unstructured":"Riwanto M, Rohrer L, von Eckardstein A, Landmesser U. Dysfunctional HDL: From structure-function-relationships to biomarkers.","journal-title":"Handb Exp Pharmacol"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-3-319-09665-0_12","volume":"224","author":"Vollenweider P.","year":"2015","unstructured":"Vollenweider P. von, E.A.; Widmann, C. HDLs, diabetes, and metabolic syndrome.","journal-title":"Handb Exp Pharmacol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nm1546","volume":"13","author":"Brunham L.R.","year":"2007","unstructured":"Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment.","journal-title":"Nat Med"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MOL.0000000000000142","volume":"26","author":"Borup A.","year":"2015","unstructured":"Borup A, Christensen PM, Nielsen LB, Christoffersen C. Apolipoprotein M in lipid metabolism and cardiometabolic diseases.","journal-title":"Curr Opin Lipidol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.1103187108","volume":"108","author":"Christoffersen C.","year":"2011","unstructured":"Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlback B. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/cvr\/cvu136","volume":"103","author":"Poti F.","year":"2014","unstructured":"Poti F, Simoni M, Nofer JR. Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P).","journal-title":"Cardiovasc Res"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cca.2015.10.021","volume":"452","author":"Arora S.","year":"2016","unstructured":"Arora S, Patra SK, Saini R. HDL-A molecule with a multi-faceted role in coronary artery disease.","journal-title":"Clin Chim Acta"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12291-015-0513-1","volume":"31","author":"Mangaraj M.","year":"2016","unstructured":"Mangaraj M, Nanda R, Panda S. Apolipoprotein A-I: A molecule of diverse function.","journal-title":"Indian J Clin Biochem"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.4049\/jimmunol.1402870","volume":"194","author":"Tiniakou I.","year":"2015","unstructured":"Tiniakou I, Drakos E, Sinatkas V, Van Eck M, Zannis VI, Boumpas D, Verginis P, Kardassis D. High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function.","journal-title":"J Immunol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fphar.2015.00265","volume":"6","author":"Zamanian-Daryoush M.","year":"2015","unstructured":"Zamanian-Daryoush M, DiDonato JA. Apolipoprotein A-I and cancer.","journal-title":"Front Pharmacol"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1038\/onc.2015.307","volume":"35","author":"Gkouskou K.K.","year":"2016","unstructured":"Gkouskou KK, Ioannou M, Pavlopoulos GA, Georgila K, Siganou A, Nikolaidis G, Kanellis DC, Moore S, Papadakis KA, Kardassis D, Iliopoulos I, McDyer FA, Drakos E, Eliopoulos AG. Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis.","journal-title":"Oncogene"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1194\/jlr.R001610","volume":"51","author":"Vergeer M.","year":"2010","unstructured":"Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA. The HDL hypothesis: Does high-density lipoprotein protect from atherosclerosis?","journal-title":"J Lipid Res"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1194\/jlr.R800088-JLR200","author":"Rader D.J.","year":"2009","unstructured":"Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis.","journal-title":"J Lipid Res"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2008.12.044","volume":"206","author":"Escola-Gil J.C.","year":"2009","unstructured":"Escola-Gil JC, Rotllan N, Julve J, Blanco-Vaca F. macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection.","journal-title":"Atherosclerosis"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jacc.2007.09.060","volume":"51","author":"van der Steeg W.A.","year":"2008","unstructured":"van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.","journal-title":"J Am Coll Cardiol"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","volume":"38","author":"Madsen C.M.","year":"2017","unstructured":"Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: Two prospective cohort studies.","journal-title":"Eur Heart J"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/CIRCULATIONAHA.108.848143","volume":"120","author":"Calabresi L.","year":"2009","unstructured":"Calabresi L, Baldassarre D, Castelnuovo S, Conca P, Bocchi L, Candini C, Frigerio B, Amato M, Sirtori CR, Alessandrini P, Arca M, Boscutti G, Cattin L, Gesualdo L, Sampietro T, Vaudo G, Veglia F, Calandra S, Franceschini G. Functional lecithin: Cholesterol acyltransferase is not required for efficient atheroprotection in humans.","journal-title":"Circulation"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"E500","DOI":"10.1210\/jc.2010-0450","volume":"95","author":"Haase C.L.","year":"2010","unstructured":"Haase CL, Tybjaerg-Hansen A, Grande P, Frikke-Schmidt R. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.atherosclerosis.2009.06.005","volume":"208","author":"Frikke-Schmidt R.","year":"2010","unstructured":"Frikke-Schmidt R. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population.","journal-title":"Atherosclerosis"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/eurheartj\/ehu208","volume":"35","author":"Jansen H.","year":"2014","unstructured":"Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease.","journal-title":"Eur Heart J"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1093\/eurheartj\/ehx274","volume":"38","author":"Barter P.J.","year":"2017","unstructured":"Barter PJ, Rye KA. HDL cholesterol concentration or HDL function: Which matters?","journal-title":"Eur Heart J"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"Bowman L.","year":"2017","unstructured":"Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of anacetrapib in patients with atherosclerotic vascular disease.","journal-title":"N Engl J Med"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3899\/jrheum.141532","volume":"42","author":"Gkolfinopoulou C.","year":"2015","unstructured":"Gkolfinopoulou C, Stratikos E, Theofilatos D, Kardassis D, Voulgari PV, Drosos AA, Chroni A. Impaired antiatherogenic functions of high-density lipoprotein in patients with ankylosing spondylitis.","journal-title":"J Rheumatol"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-319-09665-0_9","volume":"224","author":"Hoekstra M.","year":"2015","unstructured":"Hoekstra M, Van Eck M. Mouse models of disturbed HDL metabolism.","journal-title":"Handb Exp Pharmacol"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1172\/JCI117412","volume":"94","author":"Paszty C.","year":"1994","unstructured":"Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.","journal-title":"J Clin Invest"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"23699","DOI":"10.1074\/jbc.M211233200","volume":"278","author":"Van Eck M.","year":"2003","unstructured":"Van Eck M, Twisk J, Hoekstra M, Van Rij BT, Van der Lans CA, Bos IS, Kruijt JK, Kuipers F, van Berkel TJ. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver.","journal-title":"J Biol Chem"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacc.2004.06.070","volume":"44","author":"Hovingh G.K.","year":"2004","unstructured":"Hovingh GK, Brownlie A, Bisoendial RJ, Dube MP, Levels JH, Petersen W, Dullaart RP, Stroes ES, Zwinderman AH, de Groot E, Hayden MR, Kuivenhoven JA, Kastelein JJ. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease.","journal-title":"J Am Coll Cardiol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S0022-2275(20)31582-0","volume":"42","author":"Navab M.","year":"2001","unstructured":"Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids.","journal-title":"J Lipid Res"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.cca.2011.03.011","volume":"412","author":"Daniil G.","year":"2011","unstructured":"Daniil G, Phedonos AA, Holleboom AG, Motazacker MM, Argyri L, Kuivenhoven JA, Chroni A. Characterization of antioxidant\/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family subjects with monogenic low HDL disorders.","journal-title":"Clin Chim Acta"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1161\/ATVBAHA.112.255711","volume":"32","author":"Holleboom A.G.","year":"2012","unstructured":"Holleboom AG, Daniil G, Fu X, Zhang R, Hovingh GK, Schimmel AW, Kastelein JJ, Stroes ES, Witztum JL, Hutten BA, Tsimikas S, Hazen SL, Chroni A, Kuivenhoven JA. Lipid oxidation in carriers of lecithin:Cholesterol acyltransferase gene mutations.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/prca.201300014","volume":"8","author":"Ljunggren S.","year":"2014","unstructured":"Ljunggren S, Levels JH, Turkina MV, Sundberg S, Bochem AE, Hovingh K, Holleboom AG, Lindahl M, Kuivenhoven JA, Karlsson H. ApoA-I mutations, L202P and K131del, in HDL from heterozygotes with low HDL-C.","journal-title":"Proteomics Clin Appl"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1158\/1541-7786.MCR-07-2195","volume":"6","author":"Hassan M.I.","year":"2008","unstructured":"Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F. Zinc alpha 2-glycoprotein: A multidisciplinary protein.","journal-title":"Mol Cancer Res"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1210\/jc.2009-0058","volume":"94","author":"Yeung D.C.","year":"2009","unstructured":"Yeung DC, Lam KS, Wang Y, Tso AW, Xu A. Serum zinc-alpha2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.atherosclerosis.2011.08.049","volume":"219","author":"Karuna R.","year":"2011","unstructured":"Karuna R, Park R, Othman A, Holleboom AG, Motazacker MM, Sutter I, Kuivenhoven JA, Rohrer L, Matile H, Hornemann T, Stoffel M, Rentsch KM. von, E.A. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism.","journal-title":"Atherosclerosis"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1194\/jlr.M051631","volume":"55","author":"Rached F.","year":"2014","unstructured":"Rached F, Santos RD, Camont L, Miname MH, Lhomme M, Dauteuille C, Lecocq S, Serrano CV, Chapman MJ, Kontush A. Defective functionality of HDL particles in familial apoA-I deficiency: relevance of alterations in HDL lipidome and proteome.","journal-title":"J Lipid Res"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2014.05.935","volume":"235","author":"Anthanont P.","year":"2014","unstructured":"Anthanont P, Polisecki E, Asztalos BF, Diffenderfer MR, Barrett PH, Millar JS, Billheimer J, Cuchel M, Rader DJ, Schaefer EJ. A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production.","journal-title":"Atherosclerosis"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacl.2015.02.005","volume":"9","author":"Anthanont P.","year":"2015","unstructured":"Anthanont P, Asztalos BF, Polisecki E, Zachariah B, Schaefer EJ. Case report: A novel apolipoprotein A-I missense mutation apoA-I (Arg149Ser)Boston associated with decreased lecithin-cholesterol acyltransferase activation and cellular cholesterol efflux.","journal-title":"J Clin Lipidol"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacl.2012.10.011","volume":"7","author":"Lee E.Y.","year":"2013","unstructured":"Lee EY, Klementowicz PT, Hegele RA, Asztalos BF, Schaefer EJ. HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature.","journal-title":"J Clin Lipidol"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0022-2275(20)37205-9","volume":"38","author":"Miccoli R.","year":"1997","unstructured":"Miccoli R, Zhu Y, Daum U, Wessling J, Huang Y, Navalesi R, Assmann G, von Eckardstein A. A natural apolipoprotein A-I variant, apoA-I (L141R)Pisa, interferes with the formation of alpha-high density lipoproteins (HDL) but not with the formation of pre beta 1-HDL and influences efflux of cholesterol into plasma.","journal-title":"J Lipid Res"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1432-1033.1984.tb08467.x","volume":"144","author":"Utermann G.","year":"1984","unstructured":"Utermann G, Haas J, Steinmetz A, Paetzold R, Rall SC, Weisgraber KH, Mahley RW. Apolipoprotein A-IGiessen (Pro143----Arg). A mutant that is defective in activating lecithin:cholesterol acyltransferase.","journal-title":"Eur J Biochem"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0021-9150(96)05982-5","volume":"128","author":"Bruckert E.","year":"1997","unstructured":"Bruckert E, von Eckardstein A, Funke H, Beucler I, Wiebusch H, Turpin G, Assmann G. The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-IMilano.","journal-title":"Atherosclerosis"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s001099900034","volume":"77","author":"Daum U.","year":"1999","unstructured":"Daum U, Langer C, Duverger N, Emmanuel F, Benoit P, Denefle P, Chirazi A, Cullen P, Pritchard PH, Bruckert E, Assmann G, von Eckardstein A. Apolipoprotein A-I (R151C)Paris is defective in activation of lecithin: cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux.","journal-title":"J Mol Med"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/01.ATV.18.3.389","volume":"18","author":"Huang W.","year":"1998","unstructured":"Huang W, Sasaki J, Matsunaga A, Nanimatsu H, Moriyama K, Han H, Kugi M, Koga T, Yamaguchi K, Arakawa K. A novel homozygous missense mutation in the apo A-I gene with apo A-I deficiency.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1172\/JCI114355","volume":"84","author":"von Eckardstein A.","year":"1989","unstructured":"von Eckardstein A, Funke H, Henke A, Altland K, Benninghoven A, Assmann G. Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I.","journal-title":"J Clin Invest"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0022-2275(20)32453-6","volume":"40","author":"Daum U.","year":"1999","unstructured":"Daum U, Leren TP, Langer C, Chirazi A, Cullen P, Pritchard PH, Assmann G, von Eckardstein A. Multiple dysfunctions of two apolipoprotein A-I variants, apoA- I(R160L)Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers.","journal-title":"J Lipid Res"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0022-2275(20)37281-3","volume":"38","author":"Leren T.P.","year":"1997","unstructured":"Leren TP, Bakken KS, Daum U, Ose L, Berg K, Assmann G, von Eckardstein A. Heterozygosity for apolipoprotein A-I(R160L)Oslo is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I\/A- II but normal levels of HDL-subclass LpA-I.","journal-title":"J Lipid Res"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1161\/01.ATV.17.11.3021","volume":"17","author":"Miettinen H.E.","year":"1997","unstructured":"Miettinen HE, Jauhiainen M, Gylling H, Ehnholm S, Palomaki A, Miettinen TA, Kontula K. Apolipoprotein A-IFIN (Leu159--&gt;Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/01.ATV.17.1.83","volume":"17","author":"Miettinen H.E.","year":"1997","unstructured":"Miettinen HE, Gylling H, Miettinen TA, Viikari J, Paulin L, Kontula K. Apolipoprotein A-IFin. Dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0022-2275(20)30194-2","volume":"43","author":"Martin-Campos J.M.","year":"2002","unstructured":"Martin-Campos JM, Julve J, Escola JC, Ordonez-Llanos J, Gomez J, Binimelis J, Gonzalez-Sastre F, Blanco-Vaca F. ApoA-I(MALLORCA) impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia.","journal-title":"J Lipid Res"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"13654","DOI":"10.1016\/S0021-9258(18)92750-X","volume":"266","author":"Deeb S.S.","year":"1991","unstructured":"Deeb SS, Cheung MC, Peng RL, Wolf AC, Stern R, Albers JJ, Knopp RH. A mutation in the human apolipoprotein A-I gene. Dominant effect on the level and characteristics of plasma high density lipoproteins.","journal-title":"J Biol Chem"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1021\/bi972888i","volume":"37","author":"Lindholm E.M.","year":"1998","unstructured":"Lindholm EM, Bielicki JK, Curtiss LK, Rubin EM, Forte TM. Deletion of amino acids Glu146--&gt;Arg160 in human apolipoprotein A-I (ApoA-ISeattle) alters lecithin: Cholesterol acyltransferase activity and recruitment of cell phospholipid.","journal-title":"Biochemistry"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/01.ATV.19.6.1447","volume":"19","author":"Han H.","year":"1999","unstructured":"Han H, Sasaki J, Matsunaga A, Hakamata H, Huang W, Ageta M, Taguchi T, Koga T, Kugi M, Horiuchi S, Arakawa K. A novel mutant, ApoA-I nichinan (Glu235--&gt;0), is associated with low HDL cholesterol levels and decreased cholesterol efflux from cells.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0021-9150(01)00496-8","volume":"159","author":"Huang W.","year":"2001","unstructured":"Huang W, Matsunaga A, Li W, Han H, Hoang A, Kugi M, Koga T, Sviridov D, Fidge N, Sasaki J. Recombinant proapoA-I(Lys107del) shows impaired lipid binding associated with reduced binding to plasma high density lipoprotein.","journal-title":"Atherosclerosis"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1172\/JCI109957","volume":"66","author":"Weisgraber K.H.","year":"1980","unstructured":"Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Sirtori CR. A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins.","journal-title":"J Clin Invest"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1172\/JCI109956","volume":"66","author":"Franceschini G.","year":"1980","unstructured":"Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family.","journal-title":"J Clin Invest"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1161\/01.CIR.103.15.1949","volume":"103","author":"Sirtori C.R.","year":"2001","unstructured":"Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, Salvetti M, Monteduro C, Zulli R, Muiesan ML, Agabiti-Rosei E. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study.","journal-title":"Circulation"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"9926","DOI":"10.1016\/S0021-9258(18)33965-6","volume":"257","author":"Franceschini G.","year":"1982","unstructured":"Franceschini G, Frosi TG, Manzoni C, Gianfranceschi G, Sirtori CR. High density lipoprotein-3 heterogeneity in subjects with the apo-AIMilano variant.","journal-title":"J Biol Chem"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1172\/JCI10727","volume":"106","author":"Clee S.M.","year":"2000","unstructured":"Clee SM, Kastelein JJ, van Dam M, Marcil M, Roomp K, Zwarts KY, Collins JA, Roelants R, Tamasawa N, Stulc T, Suda T, Ceska R, Boucher B, Rondeau C, DeSouich C, Brooks-Wilson A, Molhuizen HO, Frohlich J, Genest J, Hayden MR. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes.","journal-title":"J Clin Invest"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2010.08.062","volume":"213","author":"Candini C.","year":"2010","unstructured":"Candini C, Schimmel AW, Peter J, Bochem AE, Holleboom AG, Vergeer M, Dullaart RP, Dallinga-Thie GM, Hovingh GK, Khoo KL, Fasano T, Bocchi L, Calandra S, Kuivenhoven JA, Motazacker MM. Identification and characterization of novel loss of function mutations in ATP-binding cassette transporter A1 in patients with low plasma high-density lipoprotein cholesterol.","journal-title":"Atherosclerosis"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0021-9150(00)00643-2","volume":"156","author":"Asztalos B.F.","year":"2001","unstructured":"Asztalos BF, Brousseau ME, McNamara JR, Horvath KV, Roheim PS, Schaefer EJ. Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease.","journal-title":"Atherosclerosis"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacl.2013.11.005","volume":"8","author":"Dimick S.M.","year":"2014","unstructured":"Dimick SM, Sallee B, Asztalos BF, Pritchard PH, Frohlich J, Schaefer EJ. A kindred with fish eye disease, corneal opacities, marked high-density lipoprotein deficiency, and statin therapy.","journal-title":"J Clin Lipidol"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1194\/jlr.M600403-JLR200","volume":"48","author":"Asztalos B.F.","year":"2007","unstructured":"Asztalos BF, Schaefer EJ, Horvath KV, Yamashita S, Miller M, Franceschini G, Calabresi L. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states.","journal-title":"J Lipid Res"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.bbalip.2015.09.006","volume":"1851","author":"Ljunggren S.A.","year":"2015","unstructured":"Ljunggren SA, Levels JH, Hovingh K, Holleboom AG, Vergeer M, Argyri L, Gkolfinopoulou C, Chroni A, Sierts JA, Kastelein JJ, Kuivenhoven JA, Lindahl M, Karlsson H. Lipoprotein profiles in human heterozygote carriers of a functional mutation P297S in scavenger receptor class B1.","journal-title":"Biochim Biophys Acta"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00018-006-6091-x","volume":"63","author":"Vanhollebeke B.","year":"2006","unstructured":"Vanhollebeke B, Pays E. The function of apolipoproteins L.","journal-title":"Cell Mol Life Sci"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCRESAHA.114.302347","volume":"114","author":"Ito K.","year":"2014","unstructured":"Ito K, Bick AG, Flannick J, Friedman DJ, Genovese G, Parfenov MG, Depalma SR, Gupta N, Gabriel SB, Taylor HA, Fox ER, Newton-Cheh C, Kathiresan S, Hirschhorn JN, Altshuler DM, Pollak MR, Wilson JG, Seidman JG, Seidman C. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants.","journal-title":"Circ Res"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"e49336","DOI":"10.1371\/journal.pone.0049336","volume":"7","author":"Chantepie S.","year":"2012","unstructured":"Chantepie S, Bochem AE, Chapman MJ, Hovingh GK, Kontush A. High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity.","journal-title":"PLoS One"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.jbchem.a124516","volume":"116","author":"Ishigami M.","year":"1994","unstructured":"Ishigami M, Yamashita S, Sakai N, Arai T, Hirano K, Hiraoka H, Kameda-Takemura K, Matsuzawa Y. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins.","journal-title":"J Biochem"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0022-2275(20)40055-0","volume":"36","author":"Ohta T.","year":"1995","unstructured":"Ohta T, Nakamura R, Takata K, Saito Y, Yamashita S, Horiuchi S, Matsuda I. Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency.","journal-title":"J Lipid Res"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1172\/JCI27602","volume":"116","author":"Matsuura F.","year":"2006","unstructured":"Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway.","journal-title":"J Clin Invest"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cca.2008.12.012","volume":"402","author":"Miwa K.","year":"2009","unstructured":"Miwa K, Inazu A, Kawashiri M, Nohara A, Higashikata T, Kobayashi J, Koizumi J, Nakajima K, Nakano T, Niimi M, Mabuchi H, Yamagishi M. Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients.","journal-title":"Clin Chim Acta"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.atherosclerosis.2011.01.051","volume":"216","author":"Plengpanich W.","year":"2011","unstructured":"Plengpanich W, Le GW, Poolsuk S, Julia Z, Guerin M, Khovidhunkit W. CETP deficiency due to a novel mutation in the CETP gene promoter and its effect on cholesterol efflux and selective uptake into hepatocytes.","journal-title":"Atherosclerosis"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2016.08.014","volume":"253","author":"Tani M.","year":"2016","unstructured":"Tani M, Horvath KV, Lamarche B, Couture P, Burnett JR, Schaefer EJ, Asztalos BF. High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency.","journal-title":"Atherosclerosis"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1172\/JCI115190","volume":"87","author":"von Eckardstein A.","year":"1991","unstructured":"von Eckardstein A, Holz H, Sandkamp M, Weng W, Funke H, Assmann G. Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.","journal-title":"J Clin Invest"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/cge.12201","volume":"85","author":"Bochem A.E.","year":"2014","unstructured":"Bochem AE, van Capelleveen JC, Dallinga-Thie GM, Schimmel AW, Motazacker MM, Tietjen I, Singaraja RR, Hayden MR, Kastelein JJ, Stroes ES, Hovingh GK. Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families.","journal-title":"Clin Genet"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00041433-200404000-00008","volume":"15","author":"Zannis V.I.","year":"2004","unstructured":"Zannis VI, Chroni A, Kypreos KE, Kan HY, Cesar TB, Zanni EE, Kardassis D. Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer.","journal-title":"Curr Opin Lipidol"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.1021\/bi7003203","volume":"46","author":"Koukos G.","year":"2007","unstructured":"Koukos G, Chroni A, Duka A, Kardassis D, Zannis VI. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN.","journal-title":"Biochemistry"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"21292","DOI":"10.1074\/jbc.M100463200","volume":"276","author":"McManus D.C.","year":"2001","unstructured":"McManus DC, Scott BR, Franklin V, Sparks DL, Marcel YL. Proteolytic degradation and impaired secretion of an apolipoprotein A-I mutant associated with dominantly inherited hypoalphalipoproteinemia.","journal-title":"J Biol Chem"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.atherosclerosis.2015.08.028","volume":"243","author":"Tiniakou I.","year":"2015","unstructured":"Tiniakou I, Kanaki Z, Georgopoulos S, Chroni A, Van Eck M, Fotakis P, Zannis VI, Kardassis D. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice.","journal-title":"Atherosclerosis"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bbalip.2011.08.019","volume":"1821","author":"Sorci-Thomas M.G.","year":"2012","unstructured":"Sorci-Thomas MG, Zabalawi M, Bharadwaj MS, Wilhelm AJ, Owen JS, Asztalos BF, Bhat S, Thomas MJ. Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice.","journal-title":"Biochim Biophys Acta"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/BJ20070296","volume":"406","author":"Koukos G.","year":"2007","unstructured":"Koukos G, Chroni A, Duka A, Kardassis D, Zannis VI. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: The abnormal HDL phenotypes can be corrected by treatment with LCAT.","journal-title":"Biochem J"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1365-2796.2011.02381.x","volume":"270","author":"Haase C.L.","year":"2011","unstructured":"Haase CL, Frikke-Schmidt R, Nordestgaard BG, Kateifides AK, Kardassis D, Nielsen LB, Andersen CB, Kober L, Johnsen AH, Grande P, Zannis VI, Tybjaerg-Hansen A. Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels.","journal-title":"J Intern Med"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/S0022-2275(20)34945-2","volume":"38","author":"Bielicki J.K.","year":"1997","unstructured":"Bielicki JK, Forte TM, McCall MR, Stoltzfus LJ, Chiesa G, Sirtori CR, Franceschini G, Rubin EM. High density lipoprotein particle size restriction in apolipoprotein A-I(Milano) transgenic mice.","journal-title":"J Lipid Res"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1074\/jbc.M207335200","volume":"278","author":"Parolini C.","year":"2003","unstructured":"Parolini C, Chiesa G, Zhu Y, Forte T, Caligari S, Gianazza E, Sacco MG, Sirtori CR, Rubin EM. Targeted replacement of mouse apolipoprotein A-I with human ApoA-I or the mutant ApoA-IMilano. Evidence of APOA-IM impaired hepatic secretion.","journal-title":"J Biol Chem"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1161\/01.ATV.19.5.1257","volume":"19","author":"Franceschini G.","year":"1999","unstructured":"Franceschini G, Calabresi L, Chiesa G, Parolini C, Sirtori CR, Canavesi M, Bernini F. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/ATVBAHA.107.148403","volume":"27","author":"Weibel G.L.","year":"2007","unstructured":"Weibel GL, Alexander ET, Joshi MR, Rader DJ, Lund-Katz S, Phillips MC, Rothblat GH. Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1111\/j.1582-4934.2008.00614.x","volume":"13","author":"Cimmino G.","year":"2009","unstructured":"Cimmino G, Ibanez B, Vilahur G, Speidl WS, Fuster V, Badimon L, Badimon JJ. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano).","journal-title":"J Cell Mol Med"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/ATVBAHA.115.307052","volume":"36","author":"Kempen H.J.","year":"2016","unstructured":"Kempen HJ, Asztalos BF, Moerland M, Jeyarajah E, Otvos J, Kallend DG, Bellibas SE, Wijngaard PL. High-density lipoprotein subfractions and cholesterol efflux capacities after infusion of MDCO-216 (apolipoprotein a-imilano\/palmitoyl-oleoyl-phosphatidylcholine) in healthy volunteers and stable coronary artery disease patients.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1021\/acs.biochem.5b00180","volume":"54","author":"Fotakis P.","year":"2015","unstructured":"Fotakis P, Kuivenhoven JA, Dafnis E, Kardassis D, Zannis VI. The effect of natural LCAT mutations on the biogenesis of HDL.","journal-title":"Biochemistry"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"10063","DOI":"10.1016\/S0021-9258(18)90928-2","volume":"259","author":"Rall S.C.","year":"1984","unstructured":"Rall SC, Weisgraber KH, Mahley RW, Ogawa Y, Fielding CJ, Utermann G, Haas J, Steinmetz A, Menzel HJ, Assmann G. Abnormal lecithin:cholesterol acyltransferase activation by a human apolipoprotein A-I variant in which a single lysine residue is deleted.","journal-title":"J Biol Chem"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF00207375","volume":"96","author":"Nofer J.R.","year":"1995","unstructured":"Nofer JR, von Eckardstein A, Wiebusch H, Weng W, Funke H, Schulte H, Kohler E, Assmann G. Screening for naturally occurring apolipoprotein A-I variants: apo A-I(delta K107) is associated with low HDL-cholesterol levels in men but not in women.","journal-title":"Hum Genet"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1161\/01.ATV.15.9.1294","volume":"15","author":"Tilly-Kiesi M.","year":"1995","unstructured":"Tilly-Kiesi M, Zhang Q, Ehnholm S, Kahri J, Lahdenpera S, Ehnholm C, Taskinen MR. ApoA-IHelsinki (Lys107--&gt;0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/01.ATV.17.5.873","volume":"17","author":"Tilly-Kiesi M.","year":"1997","unstructured":"Tilly-Kiesi M, Lichtenstein AH, Ordovas JM, Dolnikowski G, Malmstrom R, Taskinen MR, Schaefer EJ. Subjects with ApoA-I(Lys107--&gt;0) exhibit enhanced fractional catabolic rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI with AII).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0021-9150(96)05992-8","volume":"128","author":"Tilly-Kiesi M.","year":"1997","unstructured":"Tilly-Kiesi M, Packard CJ, Kahri J, Ehnholm C, Shepherd J, Taskinen MR. metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107--&gt;0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency.","journal-title":"Atherosclerosis"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0021-9150(85)90063-2","volume":"58","author":"Franceschini G.","year":"1985","unstructured":"Franceschini G, Sirtori CR, Bosisio E, Gualandri V, Orsini GB, Mogavero AM, Capurso A. Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns.","journal-title":"Atherosclerosis"},{"key":"ref=157","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/CIRCULATIONAHA.105.540427","volume":"112","author":"Hovingh G.K.","year":"2005","unstructured":"Hovingh GK, Hutten BA, Holleboom AG, Petersen W, Rol P, Stalenhoef A, Zwinderman AH, de Groot E, Kastelein JJ, Kuivenhoven JA. Compromised LCAT function is associated with increased atherosclerosis.","journal-title":"Circulation"},{"key":"ref=158","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1172\/JCI118348","volume":"96","author":"Kuivenhoven J.A.","year":"1995","unstructured":"Kuivenhoven JA. van Voorst tot Voorst EJ; Wiebusch, H.; Marcovina, S.M.; Funke, H.; Assmann, G.; Pritchard, P.H.; Kastelein, J.J. A unique genetic and biochemical presentation of fish-eye disease.","journal-title":"J Clin Invest"},{"key":"ref=159","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1194\/jlr.M600405-JLR200","volume":"48","author":"van der Steeg W.A.","year":"2007","unstructured":"van der Steeg WA, Hovingh GK, Klerkx AH, Hutten BA, Nootenboom IC, Levels JH. van, Tol A.; Dallinga-Thie, G.M.; Zwinderman, A.H.; Kastelein, J.J.; Kuivenhoven, J.A. Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians.","journal-title":"J Lipid Res"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/0006-291X(90)90542-U","volume":"170","author":"Yamashita S.","year":"1990","unstructured":"Yamashita S, Hui DY, Sprecher DL, Matsuzawa Y, Sakai N, Tarui S, Kaplan D, Wetterau JR, Harmony JA. Total deficiency of plasma cholesteryl ester transfer protein in subjects homozygous and heterozygous for the intron 14 splicing defect.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/342448a0","volume":"342","author":"Brown M.L.","year":"1989","unstructured":"Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H, Takeda R, Tall AR. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins.","journal-title":"Nature"},{"key":"ref=162","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0022-2275(20)30146-2","volume":"43","author":"Peterson J.","year":"2002","unstructured":"Peterson J, Ayyobi AF, Ma Y, Henderson H, Reina M, Deeb SS, Santamarina-Fojo S, Hayden MR, Brunzell JD. Structural and functional consequences of missense mutations in exon 5 of the lipoprotein lipase gene.","journal-title":"J Lipid Res"},{"key":"ref=163","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1258\/acb.2007.007080","volume":"45","author":"Hooper A.J.","year":"2008","unstructured":"Hooper AJ, Crawford GM, Brisbane JM, Robertson K, Watts GF, van Bockxmeer FM, Burnett JR. Familial lipoprotein lipase deficiency caused by known (G188E) and novel (W394X) LPL gene mutations.","journal-title":"Ann Clin Biochem"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.atherosclerosis.2005.03.008","volume":"183","author":"Parolini C.","year":"2005","unstructured":"Parolini C, Chiesa G, Gong E, Caligari S, Cortese MM, Koga T, Forte TM, Rubin EM. Apolipoprotein A-I and the molecular variant apoA-I(Milano): Evaluation of the antiatherogenic effects in knock-in mouse model.","journal-title":"Atherosclerosis"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/160418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T23:12:35Z","timestamp":1660605155000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/160418\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":164,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,5,21]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867325666180313114950","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}